Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once Daily PMR vs Twice Daily Pletaal in Intermittent Claudication
NCT06886620Phase 3Terminated
- Sponsor
- Genovate Biotechnology
- Start
- Mar 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cilostazol in intermittent claudication (IC) (2 arms), sponsored by Genovate Biotechnology. Primary endpoint: Initial Claudication Distance at 24 weeks. Started Mar 2016; status: terminated.
02
Drugs
cilostazol
03
Conditions
intermittent claudication (IC)
Beyond the preview
Go deeper on NCT06886620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06886620.